Provectus announces data from PV-10 Phase 2 study on metastatic melanoma

Apr 10 2012

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012.

Professor Merrick Ross, M.D. of the MD Anderson Cancer Center in Houston, Texas, is scheduled to present at the HemOnc Today Conference in New York City. His presentation, entitled "Update on Intralesional Ablative Therapies" will begin at 1:55 p.m. EDT. Included in his discussion will be information about PV-10's Phase 2 studies, for which he is a Principal Investigator.

Dr. Craig Dees, PhD, CEO of Provectus said, "This is an exciting time for Provectus as we continue our development of PV-10, and make preparations for our pivotal Phase 3 study design. We expect Dr. Ross's presentation will give additional information about the Phase 2 trial of PV-10 for metastatic melanoma, and specifically, its systemic effect. This information, in concert with the recent immunology data presented at the Society of Surgical Oncology, we believe, will provide more insight to the medical community about the role that PV-10 can play in combating metastatic melanoma."

Source: Provectus Pharmaceuticals, Inc.